AIMS: Neuropad is a simple visual indicator test, with moderate diagnostic performance for diabetic peripheral neuropathy. As it assesses sweating, which is a measure of cholinergic small nerve fibre function, we compared its diagnostic performance against established measures of both large and, more specifically, small fibre damage in patients with diabetes. METHODS: One hundred and twenty-seven participants (89 without diabetic peripheral neuropathy and 38 with) aged 57 ± 9.7 years underwent assessment with Neuropad, large nerve fibre assessments: Neuropathy Disability Score, vibration perception threshold, peroneal motor nerve conduction velocity; small nerve fibre assessments: neuropathy symptoms (Diabetic Neuropathy Symptoms score) corneal nerve fibre length and warm perception threshold. RESULTS: Neuropad has a high sensitivity but moderate specificity against large fibre neuropathy assessments: Neuropathy Disability Score (> 2) 70% and 50%, vibration perception threshold (> 14 V) 83% and 53%, and peroneal motor nerve conduction velocity (< 42 m/s) 81% and 54%, respectively. However, the diagnostic accuracy of Neuropad was significantly improved against corneal nerve fibre length (< 14 mm/mm2) with a sensitivity and specificity of 83% and 80%, respectively. Furthermore, the area under the curve for corneal nerve fibre length (85%) was significantly greater than with the Neuropathy Disability Score (66%, P = 0.01) and peroneal motor nerve conduction velocity (70%, P = 0.03). For neuropathic symptoms, sensitivity was 78% and specificity was 60%. CONCLUSIONS: The data show the improved diagnostic performance of Neuropad against corneal nerve fibre length. This study underlines the importance of Neuropad as a practical diagnostic test for small fibre neuropathy in patients with diabetes.
AIMS: Neuropad is a simple visual indicator test, with moderate diagnostic performance for diabetic peripheral neuropathy. As it assesses sweating, which is a measure of cholinergic small nerve fibre function, we compared its diagnostic performance against established measures of both large and, more specifically, small fibre damage in patients with diabetes. METHODS: One hundred and twenty-seven participants (89 without diabetic peripheral neuropathy and 38 with) aged 57 ± 9.7 years underwent assessment with Neuropad, large nerve fibre assessments: Neuropathy Disability Score, vibration perception threshold, peroneal motor nerve conduction velocity; small nerve fibre assessments: neuropathy symptoms (DiabeticNeuropathy Symptoms score) corneal nerve fibre length and warm perception threshold. RESULTS: Neuropad has a high sensitivity but moderate specificity against large fibre neuropathy assessments: Neuropathy Disability Score (> 2) 70% and 50%, vibration perception threshold (> 14 V) 83% and 53%, and peroneal motor nerve conduction velocity (< 42 m/s) 81% and 54%, respectively. However, the diagnostic accuracy of Neuropad was significantly improved against corneal nerve fibre length (< 14 mm/mm2) with a sensitivity and specificity of 83% and 80%, respectively. Furthermore, the area under the curve for corneal nerve fibre length (85%) was significantly greater than with the Neuropathy Disability Score (66%, P = 0.01) and peroneal motor nerve conduction velocity (70%, P = 0.03). For neuropathic symptoms, sensitivity was 78% and specificity was 60%. CONCLUSIONS: The data show the improved diagnostic performance of Neuropad against corneal nerve fibre length. This study underlines the importance of Neuropad as a practical diagnostic test for small fibre neuropathy in patients with diabetes.
Authors: N Papanas; K Papatheodorou; D Christakidis; D Papazoglou; G Giassakis; H Piperidou; C Monastiriotis; E Maltezos Journal: Exp Clin Endocrinol Diabetes Date: 2005-04 Impact factor: 2.949
Authors: C A Abbott; A L Carrington; H Ashe; S Bath; L C Every; J Griffiths; A W Hann; A Hussein; N Jackson; K E Johnson; C H Ryder; R Torkington; E R E Van Ross; A M Whalley; P Widdows; S Williamson; A J M Boulton Journal: Diabet Med Date: 2002-05 Impact factor: 4.359
Authors: R A Malik; E A Masson; A K Sharma; R H Lye; A K Ah-See; A M Compton; D R Tomlinson; S P Hanley; A J Boulton Journal: Diabetologia Date: 1990-05 Impact factor: 10.122
Authors: Christina Brock; Birgitte Brock; Anne Grave Pedersen; Asbjørn Mohr Drewes; Niels Jessen; Adam D Farmer Journal: World J Diabetes Date: 2016-08-25
Authors: G Ponirakis; M N Odriozola; S Odriozola; I N Petropoulos; S Azmi; H Fadavi; U Alam; O Asghar; A Marshall; A Miro; A Kheyami; A Al-Ahmar; M B Odriozola; A Odriozola; R A Malik Journal: Diabetes Res Clin Pract Date: 2016-01-14 Impact factor: 5.602
Authors: Georgios Ponirakis; Hassan Fadavi; Ioannis N Petropoulos; Shazli Azmi; Maryam Ferdousi; Mohammad A Dabbah; Ahmad Kheyami; Uazman Alam; Omar Asghar; Andrew Marshall; Mitra Tavakoli; Ahmed Al-Ahmar; Saad Javed; Maria Jeziorska; Rayaz A Malik Journal: J Diabetes Res Date: 2015-05-12 Impact factor: 4.011
Authors: Jamie Burgess; Bernhard Frank; Andrew Marshall; Rashaad S Khalil; Georgios Ponirakis; Ioannis N Petropoulos; Daniel J Cuthbertson; Rayaz A Malik; Uazman Alam Journal: Diagnostics (Basel) Date: 2021-01-24